Pharma Sales Hit Record Rs. 1.251 Trillion, Yet Pakistanis Buy Fewer Medicines

Notably, the retail pharmaceutical market in Pakistan reached Rs. Although medicine volumes rose by less than 1.0 per cent, data compiled by the pharmaceutical industry and the Drug Regulatory Authority of Pakistan (Drap) stated, 1.251 trillion in FY26, posting value expansion of.

Key points

• 316 billion during April-June 2026, up 15.04 per cent from the same quarter of the preceding year.
• These leading firms were Getz Pharma, Abbott, Sami Pharmaceuticals, GlaxoSmithKline, Martin Dow, Hilton Pharma, High-Q, and OBS.
• 1.089 trillion in the corresponding 12-month period ending June 2025, compared with Rs.
• 252.13 billion, a 20 per cent share, with expansion of 8.76 per cent.
• Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.

In practice, the latest market assessment places the retail drug business at regarding $4.45 billion and indicates that sales expansion continued to outpace the rise in packs and units sold, reflecting cost adjustments, new product introductions, and a shift towards higher-value medicines.

Notably, the market was valued at Rs. 1.089 trillion in the corresponding 12-month period ending June 2025, compared with Rs. 918.22 billion in June 2024 and Rs. 655.02 billion in June 2022. This represents a compound annual expansion rate of 17.55 per cent over four years.

Nevertheless, the total number of medicine units sold rose only 0.93 per cent to 3.80 billion during the latest 12 months, from 3.765 billion a year earlier. Industry authorities stated the slow volume expansion underlined the pressure on household purchasing power and the widening cost of treatment for patients.

National pharmaceutical firms retained their dominant position, accounting for Rs. 998.54 billion, or almost 80 per cent, of the market. Their sales grew 16.53 per cent, faster than the overall industry rate.

Multinational firms recorded sales of Rs. 252.13 billion, a 20 per cent share, with expansion of 8.76 per cent. While national businesses' volumes rose 2.98 per cent to 3.006 billion units, their unit sales, nevertheless, declined 6.16 per cent to 794 million.

Meanwhile, the market's expansion rate has moderated from the high double-digit increases seen in earlier periods. Value expansion stood at 22.4 per cent in FY24, declined to 18.56 per cent by FY25, and further eased to 14.88 per cent by FY26.

Quarterly sales reached Rs. 316 billion during April-June 2026, up 15.04 per cent from the same quarter of the preceding year. Volume expansion during the quarter was 1.49 per cent. PMDC Announces New Titles for Doctors Under Training.

When the market touched Rs, the industry recorded its highest-ever monthly retail sales in October 2025. 110.89 billion. Sales remained above Rs. 100 billion in a number of subsequent months, including December 2025, March 2026, April 2026, and June 2026.

Meanwhile, a total of 102 pharmaceutical firms crossed Rs. 1 billion in annual retail sales and together controlled 96.63 per cent of the market, according to the assessment. Eight firms had sales above Rs. 40 billion and jointly held a 37.89 per cent market share.

These leading firms were Getz Pharma, Abbott, Sami Pharmaceuticals, GlaxoSmithKline, Martin Dow, Hilton Pharma, High-Q, and OBS. Their combined sales were estimated at Rs. Though their expansion of 10.82 per cent was below the overall market rate, 474 billion.

Another 22 firms with sales above Rs. 10 billion accounted for Rs. 475 billion, or 37.97 per cent of the market. While 17 firms in the Rs, their expansion was 12.25 per cent. 5 billion-plus category collectively held a 9.27 per cent share and recorded expansion of 23.55 per cent.

Among national firms, Getz Pharma remained the largest, with retail sales of Rs. 85.27 billion and annual expansion of 19.33 per cent. Sami Pharmaceuticals followed with Rs. While Martin Dow recorded Rs, 69.23 billion. 52 billion, Hilton Pharma Rs. 46.6 billion, and High-Q Rs. 43 billion.

Ferozsons Laboratories was among the faster-growing sizeable local businesses, with sales increasing 33.18 per cent to Rs. 20.98 billion. PharmEvo grew 24.45 per cent to Rs. While CCL grew 21.26 per cent to Rs, 24.66 billion. 32.22 billion.

Abbott remained the largest multinational firm, reporting Rs. 70.08 billion in retail sales, followed by GSK at Rs. 64.83 billion and Haleon at Rs. 38.64 billion. Nestle's pharmaceutical and nutrition-related retail business grew 32.41 per cent to Rs. 22.84 billion.

In practice, the assessment additionally demonstrated rapid expansion in the new-medicine segment. A total of 989 products were introduced in the 12 months ending June 2026, excluding certain diagnostic and miscellaneous categories, with national businesses launching 982 products and multinationals seven.

These new launches generated sales of Rs. 19.18 billion, equivalent to 1.53 per cent of the total retail pharmaceutical market. Stay Connected with ProPakistani.

Obtain the latest business news, market insights, and economic updates wherever you prefer. Follow on Google Discover.

Add as a preferredSource on Google Follow on Google News Join WhatsApp.

For now, pharma Sales Hit Record Rs. 1.251 Trillion, Yet Pakistanis Buy Fewer Medicines remains the part of the story worth watching, and further updates are likely as more details are confirmed.